Inflammatix: Raises $32M in Series C Funding

0
112
Inflammatix: Raises $32M in Series C Funding

Inflammatix: Raises $32M in Series C Funding

  • Inflammatix raises $32M, plus a BARDA contract, for its point-of-care infection diagnostics
  • The company also intends to use the funds to advance its rapid HostDx™ tests through commercial launch in Europe and US
  • Inflammatix’s tests also use machine learning algorithms to parse the expression of multiple immune system genes
  • It designed to produce point-of-care results in 30 minutes or less
  • Then the company said it plans to submit its tests for FDA review in 2021
  • The Series C funding comes on the heels of the Burlingame, California-based firm inking a long-term, cost-sharing contract in November 2019